Oncternal Therapeutics Inc (OQ:ONCT)

Business Focus: Biotechnology & Medical Research

Latest 10 SEC filings (by transaction date) for ONCT within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET April 20th, 2024
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Apr 10/24 Apr 8/24 Wills Robert James Direct Ownership Common Stock P - Open market or private purchase 3,086 $8.96
Apr 1/24 Mar 28/24 Wills Robert James Direct Ownership Common Stock P - Open market or private purchase 6,914 $8.48
Feb 27/24 Feb 23/24 Hale David F Indirect Ownership Common Stock P - Open market or private purchase 266 $9.04
Feb 27/24 Feb 23/24 Hale David F Direct Ownership Common Stock P - Open market or private purchase 714 $9.04
Feb 27/24 Feb 23/24 Wills Robert James Direct Ownership Common Stock S - Open market or private sale -980 $9.04
Feb 15/24 Feb 14/24 Breitmeyer James B Indirect Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 6,200  
Feb 15/24 Feb 14/24 Breitmeyer James B Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 28,400  
Feb 15/24 Feb 14/24 Leavitt Chase C. Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 14,200  
Feb 15/24 Feb 14/24 Krishnan Rajesh Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 17,700  
Feb 15/24 Feb 14/24 Yazji Salim Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 14,200  
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for ONCT within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET April 20th, 2024
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Apr 10/24 Apr 8/24 Wills Robert James Direct Ownership Common Stock P - Open market or private purchase 3,086 $8.96
Apr 1/24 Mar 28/24 Wills Robert James Direct Ownership Common Stock P - Open market or private purchase 6,914 $8.48
Feb 27/24 Feb 23/24 Hale David F Indirect Ownership Common Stock P - Open market or private purchase 266 $9.04
Feb 27/24 Feb 23/24 Hale David F Direct Ownership Common Stock P - Open market or private purchase 714 $9.04
Feb 27/24 Feb 23/24 Wills Robert James Direct Ownership Common Stock S - Open market or private sale -980 $9.04
Feb 15/24 Feb 14/24 Breitmeyer James B Indirect Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 6,200  
Feb 15/24 Feb 14/24 Breitmeyer James B Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 28,400  
Feb 15/24 Feb 14/24 Leavitt Chase C. Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 14,200  
Feb 15/24 Feb 14/24 Krishnan Rajesh Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 17,700  
Feb 15/24 Feb 14/24 Yazji Salim Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 14,200  
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $ONCT

  • No tweets found

Competitors

Competitors with Recent Insider Filings
Medpace Holdings (OQ:MEDP)
United Therapeutics (OQ:UTHR)
Disc Medicine (OQ:IRON)

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.